Basal Insulin Peglispro Demonstrates Preferential Hepatic vs. Peripheral Action Relative to Insulin Glargine in Healthy Subjects

被引：0
|
作者：
Henry, Robert R.
Mudaliar, Sunder
Choi, Siak Leng
Ciaraldi, Theodore P.
Armstrong, Debra A.
Pettus, Jeremy
Garhyan, Parag
Knadler, Mary P.
Jacober, Scott J.
Lam, Eric Chen Quin
Linnebjerg, Helle
Porksen, Niels
Prince, Melvin J.
Sinha, Vikram P.
机构：
来源：
DIABETES | 2014年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
886-P
引用
收藏
页码：A226 / A226
页数：1
相关论文
共 50 条
  • [41] An euglycaemic glucose clamp study to evaluate the relative bioavailability of LY2963016 to insulin glargine in healthy Chinese subjects
    Ji, Y.
    Yu, Y.
    Wang, F.
    Linnebjerg, H.
    Pratt, E. J.
    Li, H.
    Liu, H.
    Tham, L. S.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S336 - S337
  • [42] A Euglycemic Glucose Clamp Study to Evaluate the Bioavailability of LY2963016 Relative to Insulin Glargine in Healthy Chinese Subjects
    Liu, Hui
    Wang, Feng
    Ji, Yongjia
    Ma, Tianyang
    Li, Hongying
    Linnebjerg, Helle
    Chua, Laiyi
    Tham, Lai San
    Yu, Yerong
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (12): : 1452 - 1459
  • [43] Efficacy and Safety of Insulin Glargine vs. NPH Insulin in Subjects With Type 2 Diabetes Mellitus Uncontrolled on Oral Agents: A Pooled Analysis of RCT Data
    Bolli, Geremia B.
    Porcellati, Francesca
    Lin, Jay
    Wang, Edward
    Lucidi, Paolo
    Fanelli, Carmine G.
    DIABETES, 2012, 61 : A265 - A265
  • [44] Assessment of treatment satisfaction in long-acting insulin analogues: Evidence from a basal-bolus regimen treating type 1 diabetic patients with insulin detemir vs. insulin glargine
    Brod, Meryl
    Lammert, Morten
    DIABETES, 2006, 55 : A558 - A558
  • [45] More Physiological Circulating Insulin and Modulation of Hepatic Glucose Production with Insulin Glargine U300 vs. U100 in Type 1 Diabetes
    Porcellati, Francesca
    Lucidi, Paola
    Andreoli, Anna Marinelli
    Cioli, Patrizia
    Candeloro, Paola
    Bolli, Geremia B.
    Fanelli, Carmine G.
    DIABETES, 2017, 66 : A269 - A269
  • [46] Efficacy and Safety of Exenatide QW vs. Placebo Added to Insulin Glargine in Uncontrolled Basal-Insulin Treated Type 2 Diabetes: DURATION-7 Trial
    Frias, Juan P.
    Rosenstock, Julio
    Somogyi, Aniko
    Jabbour, Serge A.
    Wang, Hui
    Hardy, Elise
    Guja, Cristian
    DIABETES, 2017, 66 : A34 - A35
  • [47] Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes
    Bolli, G. B.
    Songini, M.
    Trovati, M.
    Del Prato, S.
    Ghirlanda, G.
    Cordera, R.
    Trevisan, R.
    Riccardi, G.
    Noacco, C.
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2009, 19 (08) : 571 - 579
  • [48] INVIVO KINETICS OF INSULIN ACTION ON PERIPHERAL GLUCOSE DISPOSAL AND HEPATIC GLUCOSE OUTPUT IN NORMAL AND OBESE SUBJECTS
    PRAGER, R
    WALLACE, P
    OLEFSKY, JM
    JOURNAL OF CLINICAL INVESTIGATION, 1986, 78 (02): : 472 - 481
  • [49] ORAL VANADYL SULFATE (VS) IMPROVES HEPATIC AND PERIPHERAL INSULIN (INS) SENSITIVITY IN NIDDM BUT NOT IN OBESE NONDIABETIC SUBJECTS
    COHEN, N
    HALBERSTAM, M
    SHLIMOVICH, P
    ROSSETTI, L
    SHAMOON, H
    DIABETES, 1995, 44 : A166 - A166
  • [50] Lower basal insulin dose requirements, reduction of nocturnal hypoglycemic episodes and improvement of blood glucose control with insulin glargine vs previous NPH treatment in subjects with Type 1 Diabetes
    Antuña, R
    DIABETOLOGIA, 2004, 47 : A304 - A304
12345